Aggiornamento aziendale22 ott 2026ENPharming Group announces third quarter 2026 revenues above market expectationsPharming Group N.V.Company newsroom
Aggiornamento aziendale14 ott 2026ENPharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026Pharming Group N.V.Company newsroom
Aggiornamento aziendale29 set 2026ENPharming announces CEO transitionPharming Group N.V.Company newsroom
Aggiornamento aziendale25 set 2026ENPharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDSPharming Group N.V.Company newsroom
Aggiornamento aziendale22 set 2026ENPharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026Pharming Group N.V.Company newsroom
Aggiornamento aziendale11 set 2026ENFDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S.Pharming Group N.V.Company newsroom
Aggiornamento aziendale9 set 2026ENPharming Group to participate in September investor conferencesPharming Group N.V.Company newsroom
Aggiornamento aziendale13 ago 2026ENPharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and olderPharming Group N.V.Company newsroom
Aggiornamento aziendale4 ago 2026ENPharming Group to participate in Canaccord Genuity 46th Annual Growth ConferencePharming Group N.V.Company newsroom
Aggiornamento aziendale30 lug 2026ENPharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic usePharming Group N.V.Company newsroom
Aggiornamento aziendale16 lug 2026ENPharming Group to report second quarter and first half 2026 financial results and provide business update on July 30Pharming Group N.V.Company newsroom
Aggiornamento aziendale4 giu 2026ENPharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDSPharming Group N.V.Company newsroom
Aggiornamento aziendale2 giu 2026ENPharming Group to participate in Fireside Chat at 2026 Jefferies Global Healthcare Conference in New YorkPharming Group N.V.Company newsroom
Aggiornamento aziendale28 mag 2026ENPharming Group announces results of 2026 Annual General Meeting of ShareholdersPharming Group N.V.Company newsroom
Aggiornamento aziendale22 mag 2026ENEuropean Commission grants marketing authorization to Pharming’s Joenja® (leniolisib) – the first approved treatment for APDS in the European UnionPharming Group N.V.Company newsroom
Aggiornamento aziendale7 mag 2026ENPharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026Pharming Group N.V.Company newsroom
Aggiornamento aziendale7 mag 2026ENPharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disordersPharming Group N.V.Company newsroom
Aggiornamento aziendale23 apr 2026ENPharming Group to report first quarter 2026 financial results and provide business update on May 7Pharming Group N.V.Company newsroom
Aggiornamento aziendale16 apr 2026ENPharming Group announces the 2026 Annual General Meeting of ShareholdersPharming Group N.V.Company newsroom
Aggiornamento aziendale7 apr 2026ENPharming Group to participate in April investor conferencesPharming Group N.V.Company newsroom
